Verity Asset Management, Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Verity Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 11, 2020	SELL	$36.08 - $45.83 $262,193 - $333,046	-7,267 Closed	0 $0
Q3 2019 Nov 01, 2019	BUY	$42.5 - $63.11 $3,145 - $4,670	74 Added 1.03%	7,267 $311,000
Q2 2019 Aug 08, 2019	BUY	$54.93 - $74.36 $119,857 - $162,253	2,182 Added 43.54%	7,193 $457,000
Q2 2019 Aug 06, 2019	SELL	$54.93 - $74.36 $171,656 - $232,375	-3,125 Reduced 38.41%	5,011 $385,000
Q1 2019 May 13, 2019	BUY	$39.87 - $69.36 $22,127 - $38,494	555 Added 7.32%	8,136 $564,000
Q4 2018 Feb 12, 2019	BUY	$38.89 - $77.3 $78,207 - $155,450	2,011 Added 36.1%	7,581 $330,000
Q3 2018 Nov 13, 2018	BUY	$71.81 - $90.15 $40,141 - $50,393	559 Added 11.16%	5,570 $425,000
Q2 2018 Aug 07, 2018	SELL	$48.54 - $85.31 $108,438 - $190,582	-2,234 Reduced 30.84%	5,011 $385,000
Q1 2018 May 02, 2018	BUY	$44.33 - $58.52 $67,026 - $88,482	1,512 Added 26.37%	7,245 $369,000
Q4 2017 Feb 07, 2018	BUY	$43.54 - $57.32 $249,614 - $328,615	5,733	5,733 $306,000

325

85.6M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.1B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Verity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Verity Asset Management, Inc. with notifications on news.